Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis

Journal of Neuroimmunology

Volumn 99, Issue 1, 1999, Pages 19-26

  Lichtinghagen, R ^a   Seifert, T ^a   Kracke, A ^a   Marckmann, S ^a   Wurster, U ^a   Heidenreich, F ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

92 kDa Gelatinase; MMP 9, matrix metalloproteinase; Multiple sclerosis; Quantitative PCR; Reverse transcription PCR; TIMP 1; TIMP 2

Indexed keywords

GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; BLOOD BRAIN BARRIER; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; INFLAMMATORY CELL; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AUTOIMMUNE DISEASES; COLLAGENASES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; ENZYME INDUCTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMANS; LEUKOCYTES; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIPLE SCLEROSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 0032828062     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(99)00094-6     Document Type: Article

References (35)

1. Anthony D.C., Ferguson B., Matyzak M.K., Miller K.M., Esiri M.M., Perry V.H. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol. Appl. Neurobiol. 23:1997;406-415.
2. Anthony D.C., Miller K.M., Ferarn S., Townsend M.J., Opdenakker G., Wells G.M.A., Clements J.M., Chandler S., Gearing A.J.H., Perry V.H. Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS. J. Neuroimmunol. 87:1998;62-72.
3. Chandler S., Miller K.M., Clements J.M., Lury J., Corkill D., Anthony D.C.C., Adams S.E., Gearing A.J.H. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J. Neuroimmunol. 72:1997;155-161.
4. Clements J.M., Cossins J.A., Wells G.M.A., Corkill D.J., Helfrich K., Wood L.M., Pigott R., Stabler G., Ward G.A., Gearing A.J.H., Miller K.M. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumor necrosis factor-alpha inhibitor. J. Neuroimmunol. 74:1997;85-94.
5. Cossins J.A., Clements J.M., Ford J., Miller K.M., Pigott R., Vos W., Van der Valk P., De Groot C.J. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol. (Berlin). 94:1997;590-598.
6. Cuzner M.L., Gveric D., Strand C., Loughlin A.J., Paemen L., Opdenakker G., Newcombe J. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J. Neuropathol. Exp. Neurol. 55:1996;1194-1204.
7. Gijbels K., Masure S., Carton H., Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J. Neuroimmunol. 41:1992;29-34.
8. Goetzl E.J., Banda M.J., Leppert D. Matrix metalloproteinases in immunity. J. Immunol. 156:1996;1-4.
9. Hafler D., Weiner H. Immunologic mechanisms and therapy in multiple sclerosis. Immunol. Rev. 144:1995;75.
10. Hartung H.P., Reiners K., Archelos J.J., Michels M., Seeldrayers P., Heidenreich F., Pflughaupt K.W., Toyka K.V. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann. Neurol. 38:1995;186-193.
11. Hewson A.K., Smith T., Leonard J.P., Cuzner M.L. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflammation Res. 44:1995;345-349.
12. Jung K., Laube C., Lein M., Lichtinghagen R., Tschesche H., Schnorr D., Loening S.A. Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. Clin. Chem. 144:1998;1060-1062.
13. Kieseier B.C., Kiefer R., Clements J.M., Miller K., Wells G.M.A., Schweitzer T., Gearing A.J.H., Hartung H.P. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain. 121:1998;159-166.
14. Lee M.A., Palace J., Stabler G., Ford J., Gearing A., Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain. 122:1999;191-197.
15. Lein M., Nowak L., Jung K., König F., Lichtinghagen R., Schnorr D., Loening S.A. Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood. Clin. Biochem. 30:1997;491-496.
16. Leppert D., Ford J., Stabler G., Grygar C., Lienert C., Huber S.et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain. 121:1998;2327-2334.
17. Leppert D., Waubant E., Bürk M.R., Oksenberg J.R., Hauser S.L. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 40:1996;846-853.
18. Leppert D., Waubant E., Galardy R., Bunett N.W., Hauser S.L. T cell gelatinases mediate basement membrane transmigration in vitro. J. Immunol. 154:1995;4379-4389.
19. Lichtinghagen R., Glaubitz R. A competitive polymerase chain reaction assay for reliable identification of Bordetella pertussis in nasopharyngeal swabs. Eur. J. Clin. Chem. Clin. Biochem. 33:1995;87-93.
20. Lichtinghagen, R., Huegel, O., Seifert, T., Boeker, K.H.W., 1999. Expression of MMP-9, TIMP-1 and TIMP-2 in peripheral blood cells in chronic hepatitis C. J. Hepatol. (submitted).
21. Liedtke W., Cannella B., Mazzaccaro R.J., Clements J.M., Miller K.M., Wucherpfennig K.W., Gearing A.J.H., Raine C.S. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann. Neurol. 44:1998;35-46.
22. Maeda A., Sobel R.A. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 55:1996;300-309.
23. Martin R., McFarland H., McFarlin D. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10:1992;153.
24. Raeymaekers L. Quantitative PCR: theoretical considerations with practical implications. Anal. Biochem. 214:1993;582-585.
25. Rieckmann P., Albrecht M., Kitze B., Weber T., Tumani H., Broocks A., Lüer W., Helwig A., Poser S. Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann. Neurol. 37:1995;82-88.
26. Ries C., Petrides P.E. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol. Chem. Hoppe-Seyler. 376:1995;345-355.
27. Rosenberg G.A., Dencoff J.E., Correa N. Jr., Reiners M., Ford C.C. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology. 46:1996;1626-1632.
28. Steinmann L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell. 85:1996;299.
29. Stetler-Stevenson W.G., Brown P.D., Onisto M., Levy A.T., Liotta L.A. Tissue inhibitor of metalloproteinase-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J. Biol. Chem. 265:1990;13933-13938.
30. Stetler-Stevenson W.G., Krutzsch H.C., Liotta L.A. Tissue inhibitor of metalloproteinase 2 (TIMP-2): a new member of the metalloproteinase inhibitor family. J. Biol. Chem. 264:1989;17374-17378.
31. Stüve O., Chabot S., Jung S.S., Williams G., Yong V.W. Chemokine enhanced migration human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9. J. Neuroimmunol. 80:1997;38-46.
32. Stüve O., Dooley N.P., Uhm J.H., Antel J.P., Francis G.S., Williams G., Yong V.W. Interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 40:1996;853-863.
33. Weber F., Polak T., Gunther A., Kubuschok B., Janovskaja J., Bitsch A., Poser S., Rieckmann P. Synergistic immunomodulatory effects of onterferon-beta 1b and the phosphodiesterase inhibitor petoxifylline in patients with relapsing-remitting multiple sclerosis. Ann. Neurol. 44:1998;27-34.
34. Woessner J.F. Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 5:1991;2145-2154.
35. Yong V.W., Chabot S., Stuve O., Williams G. Interferon beta in the treatment of multiple sclerosis. Mechanisms of action. Neurology. 51:1998;682-689.